ADC Therapeutics SA

Healthcare · Biotechnology

1.30$ -1.5% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Balance Sheet

ADC Therapeutics SA (ADCT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 279 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ADCT
Line item	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	151	–	151	151	201	201	138	138	374	374	522	514	462	464	638	618	582	520	532	491	468	507	467	355	308	372	349	322	273	322	290	323	291	279
Current Assets	263	–	142	142	139	185	123	123	116	359	506	450	393	394	568	525	488	424	438	435	380	413	376	336	290	355	333	307	258	319	287	306	277	262
Cash	-263	–	139	139	-139	182	116	116	-116	349	494	439	383	372	530	467	431	377	381	326	311	348	310	279	234	300	274	251	195	265	235	261	231	219
Cash & Short-Term Investments	263	–	139	139	139	182	116	116	116	349	494	439	383	372	530	467	431	377	381	326	311	348	310	279	234	300	274	251	195	265	235	261	231	219
Receivables	–	–	0.2	0.2	0.0	0.0	2.8	2.8	–	–	–	2.7	1.7	2.1	16	31	27	21	23	73	24	24	21	25	23	23	24	20	32	26	23	29	31	28
Inventory	–	–	1.2	1.2	–	0.0	2.5	2.5	–	–	6.5	6.5	6.5	7.7	8.0	11	12	15	16	12	18	19	23	16	16	15	16	18	17	18	18	4.2	4.8	4.9
Property, Plant & Equipment	–	–	–	6.8	6.8	6.3	6.3	–	5.5	4.9	–	4.8	11	11	12	11	11	9.7	9.9	10.0	–	–	16	–	–	–	–	–	–	–	–	–	–	–
Goodwill	–	–	–	–	–	–	–	–	-179	-179	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	–	–	6.7	6.7	8.4	8.4	8.4	8.4	187	187	9.8	10	10	12	13	14	14	15	15	14	14	14	12	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	24	–	22	24	23	23	27	27	178	178	145	178	164	220	451	452	419	405	427	411	430	516	521	503	502	503	521	525	511	521	528	509	508	508
Current Liabilities	–	–	22	22	17	17	20	20	31	31	33	40	41	51	59	74	71	74	88	82	81	81	78	68	63	58	68	80	58	65	62	70	68	86
Short-Term Debt	–	–	–	–	1.1	1.1	1.1	1.1	4.2	4.2	3.7	4.6	4.4	7.2	7.6	7.6	7.5	7.5	13	14	15	15	16	1.5	1.4	1.4	1.5	1.4	1.4	1.8	0.9	3.0	4.6	6.2
Accounts Payable	–	–	6.8	6.8	1.2	1.2	3.3	3.3	6.8	6.8	6.1	5.3	11	15	12	12	16	13	12	12	8.7	12	9.0	16	14	11	14	18	16	9.6	8.1	9.2	5.3	13
Long-Term Debt	–	–	–	–	–	–	–	–	140	107	–	108	88	134	142	125	111	97	97	97	97	97	98	113	113	114	114	114	114	114	115	112	111	110
Shareholders' Equity	249	–	126	126	126	178	111	111	111	196	376	336	298	244	187	166	163	115	105	79	38	-8.6	-54	-148	-194	-132	-172	-203	-238	-199	-238	-186	-216	-228
Retained Earnings	–	–	-332	-332	-382	-382	-449	-449	-619	-619	-639	-695	-746	-819	-891	-925	-942	-1,006	-1,057	-1,095	-1,140	-1,187	-1,235	-1,335	-1,382	-1,419	-1,463	-1,493	-1,532	-1,589	-1,630	-1,636	-1,669	-1,685
Shares Outstanding	54	54	54	54	47	73	73	73	64	63	71	77	77	77	77	76	77	77	78	81	81	81	82	82	83	96	105	105	107	114	136	150	154	155

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings